MAAT PHARMA revenue for the last year amounted to 2.23 M EUR, the most of which — 2.23 M EUR — came from its highest performing source at the moment, Microbiome Ecosystem Therapies, the year earlier bringing 1.43 M EUR. The greatest contribution to the revenue figure was made by France — last year it brought MAAT PHARMA 2.23 M EUR, and the year before that — 1.43 M EUR.